Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Cannabinoids in the management of difficult to treat pain

Authors Ethan B Russo

Published 8 February 2008 Volume 2008:4(1) Pages 245—259

DOI http://dx.doi.org/10.2147/TCRM.S1928

Ethan B Russo

GW Pharmaceuticals, Vashon, WA, USA

Abstract: This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment. Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation. Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1 receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain. Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006. Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise.

Keywords: cannabinoids, tetrahydrocannabinol, cannabidiol, analgesia, pain management, multiple sclerosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Quantification of functional abilities in Rett syndrome: a comparison between stages III and IV

Monteiro CBM, Savelsbergh GJP, Smorenburg ARP, Graciani Z, Torriani-Pasin C, de Abreu LC, Valenti VE, Kok F

Neuropsychiatric Disease and Treatment 2014, 10:1213-1222

Published Date: 3 July 2014

Patient-reported health as a prognostic factor for adverse events following percutaneous coronary intervention

Biering K, Bøtker HE, Niemann T, Hjollund NH

Clinical Epidemiology 2014, 6:61-70

Published Date: 30 January 2014

Changes in microarchitectural characteristics at the tibial epiphysis induced by collagen-induced rheumatoid arthritis over time

Lee JH, Chun KJ, Kim HS, Kim SH, Lee K-Y, Kim DJ, Lim D

Clinical Interventions in Aging 2012, 7:373-382

Published Date: 18 September 2012

Perceived satisfaction of ophthalmology residents with the current Iranian ophthalmology curriculum

Mostafaei A, Hajebrahimi S

Clinical Ophthalmology 2011, 5:1207-1210

Published Date: 26 August 2011

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

Ashish Chandwani, Jonathan Shuter

Therapeutics and Clinical Risk Management 2008, 4:1023-1033

Published Date: 10 October 2008

Effect of ramipril on renal function in patients with intermittent claudication

Simon D Hobbs, Martin W Claridge, Antonius BM Wilmink, Donald J Adam, Mark E Thomas, Andrew W Bradbury

Vascular Health and Risk Management 2008, 4:471-475

Published Date: 11 April 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

A review of solifenacin in the treatment of urinary incontinence

Ramandeep Basra, Con Kelleher

Therapeutics and Clinical Risk Management 2008, 4:117-128

Published Date: 8 February 2008

Advances in the use of topical imiquimod to treat dermatologic disorders

Francesco Lacarrubba, Maria Rita Nasca, Giuseppe Micali

Therapeutics and Clinical Risk Management 2008, 4:87-97

Published Date: 8 February 2008

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Lala M Dunbar, Derek M Tang, Robert M Manausa

Therapeutics and Clinical Risk Management 2008, 4:235-244

Published Date: 8 February 2008